With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …

Recent therapeutic advances in the management of multiple sclerosis (MS) have raised
questions about the selection of appropriate patient candidates for various treatments and, if …

Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a
valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly …

Glatiramer acetate (GA) is approved for the treatment of multiple sclerosis (MS). However,
the mechanism of action of GA in MS is still unclear. In particular, it is not known whether GA …

Multiple sclerosis is being increasingly recognized and diagnosed in children. In the past
several years, advances have been made in diagnosing multiple sclerosis in children …

Introduction The portfolio of multiple sclerosis (MS) disease modifying treatments (DMTs)
has significantly expanded over the past two decades. Given the lifelong use of MS …

Highlights•Options for disease-modifying therapies in multiple sclerosis are
emerging.•Among these are second-generation therapeutics.•The underlying concepts and …

Glatiramer acetate (Copaxone®) is a synthetic analogue of myelin basic protein, which is
thought to be involved in the pathogenesis of multiple sclerosis (MS). The therapeutic effects …

Background Copaxone is an efficacious and safe therapy that has demonstrated clinical
benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On …

Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute
to disability worsening in patients with multiple sclerosis (MS), but there is little evidence …